Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19
Cheng-Pu Sun,Jia-Tsrong Jan,I-Hsuan Wang,Hsiu-Hua Ma,Hui-Ying Ko,Ping-Yi Wu,Tzu-Jiun Kuo,Hsin-Ni Liao,Yu-Hua Lan,Zong-Lin Sie,Yen-Hui Chen,Yi-An Ko,Chun-Che Liao,Liang-Yu Chen,I-Jung Lee,Szu-I Tsung,Yun-Ju Lai,Ming-Tsai Chiang,Jian-Jong Liang,Wen-Chun Liu,Jing-Rong Wang,Joyce Pei-Yi Yuan,Yin-Shiou Lin,Yi-Ching Tsai,Shie-Liang Hsieh,Chia-Wei Li,Han-Chung Wu,Tai-Ming Ko,Yi-Ling Lin,Mi-Hua Tao
DOI: https://doi.org/10.1371/journal.ppat.1009758
IF: 7.464
2021-08-11
PLoS Pathogens
Abstract:Since the pandemic of COVID-19 has intensely struck human society, small animal model for this infectious disease is in urgent need for basic and pharmaceutical research. Although several COVID-19 animal models have been identified, many of them show either minimal or inadequate pathophysiology after SARS-CoV-2 challenge. Here, we describe a new and versatile strategy to rapidly establish a mouse model for emerging infectious diseases in one month by multi-route, multi-serotype transduction with recombinant adeno-associated virus (AAV) vectors expressing viral receptor. In this study, the proposed approach enables profound and enduring systemic expression of SARS-CoV-2-receptor hACE2 in wild-type mice and renders them vulnerable to SARS-CoV-2 infection. Upon virus challenge, generated AAV/hACE2 mice showed pathophysiology closely mimicking the patients with severe COVID-19. The efficacy of a novel therapeutic antibody cocktail RBD-chAbs for COVID-19 was tested and confirmed by using this AAV/hACE2 mouse model, further demonstrating its successful application in drug development.
microbiology,virology,parasitology